ARTICOLI Archivi - Pagina 3 di 5

Cost-effectiveness of blood culture and a multiplex real-time pcr in hematological patients with suspected sepsis: an observational propensity score-matched study

Mancini N, Sambri V, Corti C, Ghidoli N, Tolomelli G, Paolucci M, Clerici D, Carletti S, Greco R, Tassara M, Pizzorno B, Zaniolo O, Povero M, Pradelli L, Burioni R, Stanzani M, Landini MP, Ciceri F, Clementi M. – Expert Rev Mol Diagn 2014; 14(5): 623-32

Cost-effectiveness of omega-3 fatty acid supplements in parenteral nutrition therapy in hospitals: a discrete event simulation model

Pradelli L, Eandi M, Povero M, Mayer K, Muscaritoli M, Heller AR, Fries-Schaffner E. – Clin Nutr 2014; 33(5): 785-92

Real-life cost and cost-effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48-month survey

Povero M, Pradelli L, Turco P, Dal Negro RW. – Farmeconomia. Health economics and therapeutic pathways 2014; 15(2): 39-44

The economic impact associated with cerebrovascular events related to non-valvular atrial fibrillation (NVAF) in Italy: the role of apixaban

Pradelli L., Calandriello M., Di Virgilio R., Bellone M., Tubaro M. – Farmeconomia. Health economics and therapeutic pathways 2014; 15(1S): 3-4

Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective

Paggiaro P, Patel S, Nicolini G, Pradelli L, Zaniolo O, Papi A. – Respir Med 2013; 107(10): 1531-7

A cost-minimization analysis of combination therapy in hypertension: fixed-dose vs extemporary combinations

Bellone M, Sbarra P. – Farmeconomia. Health economics and therapeutic pathways 2013; 14(4): 153-160

ISPOR 2013: what’s new and what’s old?

Zaniolo O, Povero M. – Farmeconomia. Health economics and therapeutic pathways 2013; 14(4): 151-152

First-line HIV treatment: evaluation of backbone choice and its budget impact

Zaniolo O, Povero M, Bonfanti P, Borderi M, Medaglia M. – Farmeconomia. Health economics and therapeutic pathways 2013; 14(2): 75-87

Costs of treatment of haemophilia a in Italy: comparison of the use of plasma-derived and recombinant FVIII using a discrete event simulation (DES) model

Eandi M, Pradelli L, Povero M. – Farmeconomia. Health economics and therapeutic pathways 2013; 14(2): 51-74

N-3 fatty acid-enriched parenteral nutrition regimens in elective surgical and icu patients: a meta-analysis

Pradelli L, Mayer K, Muscaritoli M, Heller AR. – Crit Care 2012; 16(5): R184

A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy

Dal Negro RW, Tognella S, Pradelli L. – J Asthma 2012; 49(8): 843-8

Perceval sutureless valves in isolated and concomitant avr procedures: an economic model shows overall decrease of costs for isolated or combined operations

Pradelli L, Zaniolo O. – Farmeconomia. Health economics and therapeutic pathways 2012; 13(4): 159-174

Effectiveness and cost-effectiveness of supplemental glutamine dipeptide in total parenteral nutrition therapy for critically ill patients: a discrete event simulation model based on italian data

Pradelli L, Iannazzo S, Zaniolo O, Muscaritoli M, Eandi M. – International Journal of Technology Assessment in Health Care 2012; 28(1): 22–28

A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five european countries

Iannazzo S, Carsi M, Chiroli S. – Appl Health Econ Health Policy 2012; 10(2): 127-38

Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (copd) in Italy

Zaniolo O, Iannazzo S, Pradelli L, Miravitlles M. – Eur J Health Econ 2012; 13(1): 71-80

Gefitinib: a pharmacoeconomic profile of its use in patients with non small cell lung cancer EGFR+

Sacchi V. – Farmeconomia e percorsi terapeutici 2011; 12(2): 77-85

Cost-effectiveness evaluations of spinal neuromodulation with ziconotide continuous infusion in cancer pain in a real clinical practice

Zaniolo O, Iannazzo S, Patrucco GP, Bellini R. – Farmeconomia e percorsi terapeutici 2011; 12(2): 87-94

Tiotropium bromide in the routine care of gold stage II COPD patients: a pharmaeconomic evaluation

Zaniolo O, Carsi M, Iannazzo S. – Farmeconomia e percorsi terapeutici 2011; 12(2): 45-52

Estimation of economic consequences of gold guidelines adoption in the italian clinical practice

Zaniolo O, Bettoncelli G, Bosio G, Mantovani L, Pistelli R, Vaghi A, Villa M, Iannazzo S, Bamfi F, Frizzo V, Dal Negro RW. – Farmeconomia e percorsi terapeutici 2011; 12(1): 5-19

Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy

Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. – Eur Ann Allergy Clin Immunol 2011; 43(2): 45-53

Cost-effectiveness analysis of lhrh agonists in the treatment of metastatic prostate cancer in Italy

Iannazzo S, Pradelli L, Carsi M, Perachino M. – Value Health 2011; 14(1): 80-9

Pharmacoeconomic evaluation of the MF59–adjuvanted influenza vaccine in the elderly population in Italy

Iannazzo S. – J Prev Med Hyg 2011; 52(1):1-8

Un modello di budget impact per la valutazione economica di tocilizumab come prima linea biologica nei pazienti con artrite reumatoide di grado moderato o severo

Capri S, Benucci M, Iannazzo S, Zaniolo O, D’Arpino A. – Italian Journal of Public Health – Year 8, Volume 7, Number 2, Suppl 2, 2010: S44-53

Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy

Eandi M, Pradelli L, Iannazzo S, Chiroli S, Pontoriero G. – Pharmacoeconomics 2010; 28(11): 1041-54

Rituximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis

Benucci M, Iannazzo S, Zaniolo O, Sabadini L. – Clin Exp Rheumatol 2010; 28(5): 722-7

Organization and estimated patient-borne costs of oral anticoagulation therapy in Italy: results from a survey

Pradelli L, Iannazzo S, Zaniolo O, Botrugno P. – Appl Health Econ Health Policy 2010; 8 (2): 119-128

Cost/effectiveness model of dabigatran in the prevention of venous thromboembolism in major orthopedic surgery: adaptation for Italy

Zaniolo O, Wolowacz SE, Pradelli L. – Farmeconomia e percorsi terapeutici 2010; 11(2): 91-101

Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept

Sacchi V, Zaniolo O, Olivieri I. – Farmeconomia e percorsi terapeutici 2010; 11(2): 63-76

Tiotropium in COPD: clinical outcomes and economic evidence

Zaniolo O, Sacchi V, Dal Negro RW. – Farmeconomia e percorsi terapeutici 2010; 11(1): 27-41

The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model

Pradelli L, Iannazzo S, Zaniolo O. – Am J Cardiovasc Drugs 2009; 9: 383-392

Effectiveness and cost of treatment with maraviroc in HIV infection

Sacchi V, Pradelli L. – Farmeconomia e percorsi terapeutici 2009; 10(4): 149-159

Dabigatran in the prevention of venous thromboembolism after major orthopedic surgery

Zaniolo O. – Farmeconomia e percorsi terapeutici 2009; 10(3): 115-128

Sugammadex in antagonism of neuromuscular block in anesthesia: a clinical and economic profile

Sacchi V, Iannazzo S, Giunta F. – Farmeconomia e percorsi terapeutici 2009; 10(3): 103-114

The clinical and economic value of the dipeptide alanyl-glutamine in total parenteral nutrition of critically ill patients treated in intensive care units in Italy

Muscaritoli M, Pradelli L, Zaniolo O, Iannazzo S, Eandi M. – Farmeconomia e percorsi terapeutici 2009; 10(2): 83-92

Costs of diabetes in Italy

Zaniolo O. – Farmeconomia e percorsi terapeutici 2009; 10(2): 73-81

Pharmacoeconomic evaluation of influenza vaccination programs in elderly in Italy

Iannazzo S, Sacchi V. – Farmeconomia e percorsi terapeutici 2009; 10(2): 59-72

Solifenacin in the treatment of overactive bladder syndrome in italian patients: pharmacoeconomic evaluation

Pradelli L, Iannazzo S. – Journal of Medical Economics 2009; 12(1): 25-35

Budget impact analysis of the use of lapatinib in the treatment of breast cancer in Italy

Bamfi F, Basso F, Aglietta M, Bengala C, Lorusso V, Pronzato P, Cavallo MC, Zaniolo O, Iannazzo S. – Farmeconomia e percorsi terapeutici 2009; 10(1): 33-46